Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
Authors:
Open Access
- 1 January 2021
- journal article
- editorial
- Published by SAGE Publications in Cancer Control
- Vol. 28
Abstract
Head and neck squamous cell carcinoma (HNSCC) is a potential curative disease at its localized stage, by the use of multimodal treatment including surgery, radiation, and chemotherapy. While the metastatic stage is considered incurable and is characterized by poor prognosis. Conventional cytotoxic chemotherapy in addition to cetuximab were the only available systemic treatment with limited efficacy and modest median overall survival barely crossing the 1 year limit. Immunotherapy with PD-1 and PD-L1 inhibitors has revolutionized the treatment of multiple cancers. Recently, Immunotherapy is being extensively explored in head and neck cancer and clinical trials have shown impressive results that allowed to immune check point inhibitors to be the new standard of care. In this article we tried to explain the rationale and mechanisms of targeting the immune system in head and neck carcinoma and to report the results from the phase III clinical trials that put the immunotherapy as a new standard of care for head and neck cancer.Keywords
This publication has 14 references indexed in Scilit:
- Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinomaAnnals of Oncology, 2018
- Immune Checkpoint Inhibition in Head and Neck CancerFrontiers in Oncology, 2018
- Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinomaCancer Research, 2018
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionOral Oncology, 2018
- PD-L1 expressing circulating tumour cells in head and neck cancersBMC Cancer, 2017
- Resistance to PD1/PDL1 checkpoint inhibitionCancer Treatment Reviews, 2017
- Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for ResearchClinical Cancer Research, 2016
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsScience Translational Medicine, 2016
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysisScientific Reports, 2015
- Comprehensive genomic characterization of head and neck squamous cell carcinomasNature, 2015